Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

Kai-Yue Huang; Feng-Yun Wang; Mi Lv; Xiang-Xue Ma; Xu-Dong Tang; Lin Lv

doi:10.3748/wjg.v29.i26.4120

Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

World J Gastroenterol. 2023 Jul 14;29(26):4120-4135. doi: 10.3748/wjg.v29.i26.4120.

Authors

Kai-Yue Huang^{1

2}, Feng-Yun Wang^{1

2}, Mi Lv^{1

2}, Xiang-Xue Ma^{1

2}, Xu-Dong Tang^{1

2}, Lin Lv^{1

3}

Affiliations

¹ Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China.
² Institute of Digestive Diseases, Beijing Institute of Spleen and Stomach Disease of Traditional Chinese Medicine, Beijing 100091, China.
³ Institute of Digestive Diseases, Beijing Institute of Spleen and Stomach Disease of Traditional Chinese Medicine, Beijing 100091, China. lushangshitou@qq.com.

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disease with a significant impact on patients' quality of life and a high socioeconomic burden. And the understanding of IBS has changed since the release of the Rome IV diagnosis in 2016. With the upcoming Rome V revision, it is necessary to review the results of IBS research in recent years. In this review of IBS, we can highlight future concerns by reviewing the results of IBS research on epidemiology, overlap disorders, pathophysiology, and treatment over the past decade and summarizing the latest research.

Keywords: Irritable bowel syndrome; Overlap; Pathophysiology; Treatment.

Publication types

Review

MeSH terms

Humans
Irritable Bowel Syndrome* / diagnosis
Irritable Bowel Syndrome* / epidemiology
Irritable Bowel Syndrome* / therapy
Prevalence
Quality of Life
Severity of Illness Index